Derek Yuan is currently China General Manager of Candid Therapeutics, a company focused on developing T-cell engagers for the treatment of autoimmune disorders. Previously, he founded Prescient Advisory, an advisory company focused on China-US life sciences transactions, and also served as Executive Director of Corporate Development at Zal Lab from 2018-2022. Derek also has experience in healthcare fund management at QUAD Investment Management and started his career at UBS in pharmaceuticals equity research.